Comparative Pharmacology
Head-to-head clinical analysis: CYKLOKAPRON versus LYSTEDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYKLOKAPRON versus LYSTEDA.
CYKLOKAPRON vs LYSTEDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Competitive inhibition of plasminogen activation, reducing fibrinolysis.
1 g (10 mL) IV over 5-10 minutes every 6-8 hours; or 25-50 mg/kg/day IV divided every 6-8 hours. Oral: 1-1.5 g 3-4 times daily.
650 mg orally three times daily (total 3.9 g/day) for up to 5 days during menses.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours (renal impairment extends to 10-20 hours).
Terminal elimination half-life is approximately 2 hours (range 1.5–2.5 hours). In patients with renal impairment, half-life is significantly prolonged (up to 20 hours in severe renal impairment).
Renal: >95% as unchanged drug via glomerular filtration; minimal biliary/fecal (<5%).
Primarily renal excretion (>95% unchanged drug via glomerular filtration). Less than 5% is metabolized (mainly acylated derivative).
Category C
Category C
Antifibrinolytic
Antifibrinolytic